These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1090 related items for PubMed ID: 22483738

  • 1. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):655-60. PubMed ID: 22483738
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):1066-74. PubMed ID: 20932651
    [Abstract] [Full Text] [Related]

  • 3. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, Lillehei K, Chen C.
    J Neurooncol; 2015 Jun 15; 123(2):251-7. PubMed ID: 25920710
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.
    Radiat Oncol; 2013 Feb 20; 8():38. PubMed ID: 23425509
    [Abstract] [Full Text] [Related]

  • 5. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
    Reddy K, Gaspar LE, Kavanagh BD, Chen C.
    J Med Imaging Radiat Oncol; 2014 Dec 20; 58(6):714-21. PubMed ID: 24975917
    [Abstract] [Full Text] [Related]

  • 6. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot MC, Shenouda G.
    Int J Radiat Oncol Biol Phys; 2009 Feb 01; 73(2):473-8. PubMed ID: 18554821
    [Abstract] [Full Text] [Related]

  • 7. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, Kawasaki K, Hasegawa Y, Hara R.
    Int J Radiat Oncol Biol Phys; 2014 Mar 15; 88(4):793-800. PubMed ID: 24495592
    [Abstract] [Full Text] [Related]

  • 8. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
    Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot MC, Corredor AG, Abdulkarim B.
    Int J Radiat Oncol Biol Phys; 2017 Mar 01; 97(3):487-494. PubMed ID: 28011051
    [Abstract] [Full Text] [Related]

  • 9. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.
    J Neurosurg; 2014 Sep 01; 121(3):543-53. PubMed ID: 24995786
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
    Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):93-9. PubMed ID: 22079725
    [Abstract] [Full Text] [Related]

  • 11. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
    Morganti AG, Balducci M, Salvati M, Esposito V, Romanelli P, Ferro M, Calista F, Digesù C, Macchia G, Ianiri M, Deodato F, Cilla S, Piermattei A, Valentini V, Cellini N, Cantore GP.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):92-7. PubMed ID: 19683876
    [Abstract] [Full Text] [Related]

  • 12. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P, Galeandro M, D'Abbiero N, Podgornii A, Pisanello A, Botti A, Cagni E, Iori M, Iotti C.
    Clin Neurol Neurosurg; 2013 Sep 01; 115(9):1609-14. PubMed ID: 23453151
    [Abstract] [Full Text] [Related]

  • 13. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS, Smith KA, Stea B.
    World J Surg Oncol; 2016 Aug 24; 14(1):225. PubMed ID: 27557526
    [Abstract] [Full Text] [Related]

  • 14. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
    Beauchesne P, Quillien V, Faure G, Bernier V, Noel G, Quetin P, Gorlia T, Carnin C, Pedeux R.
    Int J Cancer; 2016 Mar 15; 138(6):1538-44. PubMed ID: 26501997
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L, Chen L, Lv S, Li Q, Chen G, Luo W, Zhou P, Li G.
    Radiat Oncol; 2019 Jun 13; 14(1):104. PubMed ID: 31196126
    [Abstract] [Full Text] [Related]

  • 16. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.
    Anticancer Res; 2003 Jun 13; 23(6D):5159-64. PubMed ID: 14981983
    [Abstract] [Full Text] [Related]

  • 17. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, Pace A, Giangaspero F, Bozzao A, Enrici RM.
    Int J Radiat Oncol Biol Phys; 2015 Jan 01; 91(1):109-15. PubMed ID: 25442339
    [Abstract] [Full Text] [Related]

  • 18. Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
    Ammirati M, Chotai S, Newton H, Lamki T, Wei L, Grecula J.
    J Clin Neurosci; 2014 Apr 01; 21(4):633-7. PubMed ID: 24380758
    [Abstract] [Full Text] [Related]

  • 19. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R, Basu A, Gupta T, Munshi A, Menon H, Sarin R, Goel A.
    Br J Neurosurg; 2007 Dec 01; 21(6):583-7. PubMed ID: 18071985
    [Abstract] [Full Text] [Related]

  • 20. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
    Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.
    Int J Radiat Oncol Biol Phys; 2017 Jul 15; 98(4):802-810. PubMed ID: 28602411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.